Register Login

PERCHERON THERAPEUTICS LTD (PERCF)

SymbolPERCF
NamePERCHERON THERAPEUTICS LTD
SectorHEALTH CARE
RegionOceania
Industry-
Address3000 Australia VA Level 30, 35 Collins Street
Telephone+61 398278999
Fax—
Email—
Websitehttps://percherontx.com/
IncorporationAU
Incorporated On2000
Employees—
Fiscal Year6/30
Public Since—
ExchangesOTC;NASDAQ
AuditorWilliam Buck Audit and Assurance;
Audit StatusAUDITED
Reporting StatusInternational Reporting: ASX - Australian Securities Exchange
CIK0001309503
Description

Percheron Therapeutics Limited is a publicly listed biotechnology company focused on the development and commercialisation of novel therapies for rare diseases. The companys lead program is avicursen (ATL1102), an antisense oligonucleotide targeting the CD49d receptor, which has been investigated in a range of inflammatory conditions, including multiple sclerosis and Duchenne muscular dystrophy.

Additional info from NASDAQ:
Heron Therapeutics Inc is a commercial-stage biotechnology company. It is focused on improving the lives of patients by developing treatments that address some of the unmet patient needs. The companys product portfolio consists of SUSTOL, ZYNRELEF, and CINVANTI. Its pipeline product is HTX-011.

Additional info from OTC:
Percheron Therapeutics Limited is a publicly listed biotechnology company focused on the development and commercialisation of novel therapies for rare diseases. The companys lead program is avicursen (ATL1102), an antisense oligonucleotide targeting the CD49d receptor, which has been investigated in a range of inflammatory conditions, including multiple sclerosis and Duchenne muscular dystrophy.

No news found.